Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 396

1.

Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease.

Shima T, Sakai K, Oya H, Katayama T, Mitsumoto Y, Mizuno M, Kanbara Y, Okanoue T.

J Gastroenterol. 2019 Sep 19. doi: 10.1007/s00535-019-01626-1. [Epub ahead of print]

PMID:
31538241
2.

Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.

Sumida Y, Okanoue T, Nakajima A; Japan Study Group of NAFLD (JSG-NAFLD).

Hepatol Res. 2019 Sep 8. doi: 10.1111/hepr.13425. [Epub ahead of print] Review.

PMID:
31495973
3.

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials.

Anstee QM, Lawitz EJ, Alkhouri N, Wong VW, Romero-Gomez M, Okanoue T, Trauner M, Kersey K, Li G, Han L, Jia C, Wang L, Chen G, Subramanian GM, Myers RP, Djedjos CS, Kohli A, Bzowej N, Younes Z, Sarin S, Shiffman ML, Harrison SA, Afdhal NH, Goodman Z, Younossi ZM.

Hepatology. 2019 Nov;70(5):1521-1530. doi: 10.1002/hep.30842. Epub 2019 Aug 19.

PMID:
31271665
4.

Is the grade of ballooned hepatocytes a significant risk factor for rapid progression of hepatic fibrosis in patients with NAFLD?

Sumida Y, Yoneda M, Okanoue T; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD).

J Gastroenterol. 2019 May;54(5):474-475. doi: 10.1007/s00535-019-01573-x. Epub 2019 Mar 26. No abstract available.

PMID:
30915535
5.

Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis.

Younossi ZM, Stepanova M, Anstee QM, Lawitz EJ, Wai-Sun Wong V, Romero-Gomez M, Kersey K, Li G, Subramanian GM, Myers RP, Djedjos CS, Okanoue T, Trauner M, Goodman Z, Harrison SA.

Clin Gastroenterol Hepatol. 2019 Nov;17(12):2552-2560.e10. doi: 10.1016/j.cgh.2019.02.024. Epub 2019 Feb 16.

PMID:
30779990
6.

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1-3 fibrosis.

Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y.

Diabetes Metab Syndr Obes. 2018 Nov 27;11:835-843. doi: 10.2147/DMSO.S184767. eCollection 2018.

7.

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.

Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.

J Gastroenterol. 2019 Apr;54(4):367-376. doi: 10.1007/s00535-018-1532-5. Epub 2018 Nov 29.

8.

Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients.

Shima T, Uto H, Ueki K, Kohgo Y, Yasui K, Nakamura N, Nakatou T, Takamura T, Kawata S, Notsumata K, Sakai K, Tateishi R, Okanoue T.

J Gastroenterol. 2019 Jan;54(1):64-77. doi: 10.1007/s00535-018-1494-7. Epub 2018 Jul 13.

PMID:
30006904
9.

Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: Multicenter validation study.

Itoh Y, Seko Y, Shima T, Nakajima T, Mizuno K, Kawamura Y, Akuta N, Ito K, Kawanaka M, Hiramatsu A, Sakamoto M, Harada K, Goto Y, Nakayama T, Kumada H, Okanoue T.

Hepatol Res. 2018 Dec;48(13):1099-1107. doi: 10.1111/hepr.13226. Epub 2018 Aug 6.

PMID:
29974624
10.

Correction to: The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.

Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A, Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD).

J Gastroenterol. 2018 Nov;53(11):1225. doi: 10.1007/s00535-018-1478-7.

PMID:
29802457
11.

The novel cutoff points for the FIB4 index categorized by age increase the diagnostic accuracy in NAFLD: a multi-center study.

Ishiba H, Sumida Y, Tanaka S, Yoneda M, Hyogo H, Ono M, Fujii H, Eguchi Y, Suzuki Y, Yoneda M, Takahashi H, Nakahara T, Seko Y, Mori K, Kanemasa K, Shimada K, Imai S, Imajo K, Kawaguchi T, Nakajima A, Chayama K, Saibara T, Shima T, Fujimoto K, Okanoue T, Itoh Y; Japan Study Group of Non-Alcoholic Fatty Liver Disease (JSG-NAFLD).

J Gastroenterol. 2018 Nov;53(11):1216-1224. doi: 10.1007/s00535-018-1474-y. Epub 2018 May 9. Erratum in: J Gastroenterol. 2018 May 25;:.

PMID:
29744597
12.

[The impact of direct-acting antiviral therapy on the diagnosis of hepatitis-C virus-associated hepatocellular carcinoma].

Takahashi A, Shima T, Kinoshita N, Yano K, Ueno T, Nishiwaki M, Yamamoto Y, Oya H, Amano I, Matsumoto J, Mitsumoto Y, Tanaka I, Sakai K, Sawai N, Mizuno C, Mizuno M, Itoh Y, Okanoue T.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(2):184-194. doi: 10.11405/nisshoshi.115.184. Japanese.

PMID:
29459562
13.

Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.

Kawaguchi T, Shima T, Mizuno M, Mitsumoto Y, Umemura A, Kanbara Y, Tanaka S, Sumida Y, Yasui K, Takahashi M, Matsuo K, Itoh Y, Tokushige K, Hashimoto E, Kiyosawa K, Kawaguchi M, Itoh H, Uto H, Komorizono Y, Shirabe K, Takami S, Takamura T, Kawanaka M, Yamada R, Matsuda F, Okanoue T.

PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.

14.

Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts the development of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease.

Kawanaka M, Tomiyama Y, Hyogo H, Koda M, Shima T, Tobita H, Hiramatsu A, Nishino K, Okamoto T, Sato S, Hara Y, Nishina S, Kawamoto H, Chayama K, Okanoue T, Hino K.

Hepatol Res. 2018 Jun;48(7):521-528. doi: 10.1111/hepr.13054. Epub 2018 Feb 9.

PMID:
29316028
15.

Retroperitoneal Perforation Caused by Migration of a Pancreatic Spontaneous Dislodgement Stent into Periampullary Diverticula.

Nishiwaki M, Mizuno C, Yano K, Oya H, Amano I, Matsumoto J, Tanaka I, Sawai N, Mizuno M, Shima T, Miyamoto Y, Okanoue T.

Intern Med. 2018 Feb 1;57(3):351-355. doi: 10.2169/internalmedicine.9054-17. Epub 2017 Nov 1.

16.

Activation of apoptosis inhibitor of macrophage is a sensitive diagnostic marker for NASH-associated hepatocellular carcinoma.

Koyama N, Yamazaki T, Kanetsuki Y, Hirota J, Asai T, Mitsumoto Y, Mizuno M, Shima T, Kanbara Y, Arai S, Miyazaki T, Okanoue T.

J Gastroenterol. 2018 Jun;53(6):770-779. doi: 10.1007/s00535-017-1398-y. Epub 2017 Oct 30.

PMID:
29086016
17.

Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.

Kobayashi N, Kumada T, Toyoda H, Tada T, Ito T, Kage M, Okanoue T, Kudo M.

Dig Dis. 2017;35(6):521-530. doi: 10.1159/000480142. Epub 2017 Oct 17.

PMID:
29040984
18.

A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.

Okanoue T, Ebise H, Kai T, Mizuno M, Shima T, Ichihara J, Aoki M.

J Gastroenterol. 2018 Jan;53(1):129-139. doi: 10.1007/s00535-017-1355-9. Epub 2017 Jun 6.

PMID:
28589339
19.

Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease.

Sakamoto M, Tsujikawa H, Effendi K, Ojima H, Harada K, Zen Y, Kondo F, Nakano M, Kage M, Sumida Y, Hashimoto E, Yamada G, Okanoue T, Koike K.

Pathol Int. 2017 Jan;67(1):1-7. doi: 10.1111/pin.12485. Epub 2016 Dec 20. Review. No abstract available.

PMID:
27995687
20.

Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.

Toyoda H, Kumada T, Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T.

J Hepatol. 2017 Mar;66(3):521-527. doi: 10.1016/j.jhep.2016.11.012. Epub 2016 Nov 25.

PMID:
27890790
21.

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study.

Kumada H, Suzuki Y, Karino Y, Chayama K, Kawada N, Okanoue T, Itoh Y, Mochida S, Toyoda H, Yoshiji H, Takaki S, Yatsuzuka N, Yodoya E, Iwasa T, Fujimoto G, Robertson MN, Black S, Caro L, Wahl J.

J Gastroenterol. 2017 Apr;52(4):520-533. doi: 10.1007/s00535-016-1285-y. Epub 2016 Nov 21.

22.

Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease.

Seki K, Shima T, Oya H, Mitsumoto Y, Mizuno M, Okanoue T.

Hepatol Res. 2017 Aug;47(9):882-889. doi: 10.1111/hepr.12829. Epub 2016 Nov 25.

PMID:
27753194
23.

[Present State of Non-B Non-C Liver Disease-and Its Monitoring.]

Shima T, Mizuno M, Okanoue T.

Rinsho Byori. 2016 May;64(4):472-479. Japanese.

PMID:
29182821
24.

Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers.

Mizuno M, Shima T, Oya H, Mitsumoto Y, Mizuno C, Isoda S, Kuramoto M, Taniguchi M, Noda M, Sakai K, Koyama N, Okanoue T.

Hepatol Res. 2017 Feb;47(2):216-225. doi: 10.1111/hepr.12710. Epub 2016 Apr 27.

PMID:
26997642
25.

Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies.

Okanoue T, Shima T, Hasebe C, Karino Y, Imazeki F, Kumada T, Minami M, Imai Y, Yoshihara H, Mita E, Morikawa T, Nishiguchi S, Kawakami Y, Nomura H, Sakisaka S, Kurosaki M, Yatsuhashi H, Oketani M, Kohno H, Masumoto A, Ikeda K, Kumada H.

Hepatol Res. 2016 Sep;46(10):992-1001. doi: 10.1111/hepr.12638. Epub 2016 Jan 18.

PMID:
26670363
26.

Alpha-fetoprotein and des-gamma-carboxy-prothrombin at twenty-four weeks after interferon-based therapy predict hepatocellular carcinoma development.

Shakado S, Sakisaka S, Chayama K, Okanoue T, Toyoda J, Izumi N, Matsumoto A, Takehara T, Ido A, Hiasa Y, Yoshioka K, Nomura H, Ueno Y, Seike M, Kumada H.

World J Hepatol. 2015 Nov 28;7(27):2757-64. doi: 10.4254/wjh.v7.i27.2757.

27.

Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining.

Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K.

Hepatology. 2016 Feb;63(2):462-73. doi: 10.1002/hep.28226. Epub 2015 Dec 14.

PMID:
26390046
28.

Effect of PNPLA3 rs738409 variant (I148 M) on hepatic steatosis, necroinflammation, and fibrosis in Japanese patients with chronic hepatitis C.

Yasui K, Kawaguchi T, Shima T, Mitsuyoshi H, Seki K, Sendo R, Mizuno M, Itoh Y, Matsuda F, Okanoue T.

J Gastroenterol. 2015 Aug;50(8):887-93. doi: 10.1007/s00535-014-1018-z. Epub 2014 Nov 26.

PMID:
25543233
29.

Efficacy of telaprevir-based therapy for difficult-to-treat patients with genotype 2 chronic hepatitis C in Japan.

Kumada H, Sato K, Takehara T, Nakamuta M, Ishigami M, Chayama K, Toyota J, Suzuki F, Nakayasu Y, Ochi M, Yamada I, Okanoue T.

Hepatol Res. 2015 Jul;45(7):745-54. doi: 10.1111/hepr.12416. Epub 2014 Nov 18.

PMID:
25196718
30.

Simple scoring system for predicting cirrhosis in nonalcoholic fatty liver disease.

Kessoku T, Ogawa Y, Yoneda M, Imajo K, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Chayama K, Tanaka S, Fujimoto K, Anzai K, Saibara T, Sata M, Itoh Y, Nakajima A, Okanoue T; Japan Study Group of NAFLD (JSG-NAFLD).

World J Gastroenterol. 2014 Aug 7;20(29):10108-14. doi: 10.3748/wjg.v20.i29.10108.

31.

Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice.

Yamaguchi K, Nishimura T, Ishiba H, Seko Y, Okajima A, Fujii H, Tochiki N, Umemura A, Moriguchi M, Sumida Y, Mitsuyoshi H, Yasui K, Minami M, Okanoue T, Itoh Y.

Liver Int. 2015 Feb;35(2):550-61. doi: 10.1111/liv.12645. Epub 2014 Aug 12.

PMID:
25066281
32.

Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease.

Shima T, Seki K, Umemura A, Ogawa R, Horimoto R, Oya H, Sendo R, Mizuno M, Okanoue T.

Hepatol Res. 2015 May;45(5):548-59. doi: 10.1111/hepr.12384. Epub 2014 Aug 13.

PMID:
24976563
33.

Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study.

Kumada H, Hayashi N, Izumi N, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Rito K, Komada Y, Seto C, Goto S.

Hepatol Res. 2015 May;45(5):501-13. doi: 10.1111/hepr.12375. Epub 2014 Jul 29.

PMID:
24961662
34.

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study.

Tateishi R, Okanoue T, Fujiwara N, Okita K, Kiyosawa K, Omata M, Kumada H, Hayashi N, Koike K.

J Gastroenterol. 2015 Mar;50(3):350-60. doi: 10.1007/s00535-014-0973-8. Epub 2014 Jun 15.

35.

Modification of a simple clinical scoring system as a diagnostic screening tool for non-alcoholic steatohepatitis in Japanese patients with non-alcoholic fatty liver disease.

Nakamura A, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Okanoue T, Nakajima A, Maeda S, Terauchi Y.

J Diabetes Investig. 2013 Nov 27;4(6):651-8. doi: 10.1111/jdi.12101. Epub 2013 May 19.

36.

Simeprevir with peginterferon/ribavirin for treatment-naïve hepatitis C genotype 1 patients in Japan: CONCERTO-1, a phase III trial.

Hayashi N, Izumi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S.

J Hepatol. 2014 Aug;61(2):219-27. doi: 10.1016/j.jhep.2014.04.004. Epub 2014 Apr 12.

PMID:
24727123
37.

Once-daily simeprevir with peginterferon and ribavirin for treatment-experienced HCV genotype 1-infected patients in Japan: the CONCERTO-2 and CONCERTO-3 studies.

Izumi N, Hayashi N, Kumada H, Okanoue T, Tsubouchi H, Yatsuhashi H, Kato M, Ki R, Komada Y, Seto C, Goto S.

J Gastroenterol. 2014 May;49(5):941-53. doi: 10.1007/s00535-014-0949-8. Epub 2014 Mar 14.

PMID:
24626851
38.

Efficacy and safety of sorafenib in very elderly patients aged 80 years and older with advanced hepatocellular carcinoma.

Jo M, Yasui K, Kirishima T, Shima T, Niimi T, Katayama T, Mori T, Funaki J, Sumida Y, Fujii H, Takami S, Kimura H, Mitsumoto Y, Minami M, Yamaguchi K, Yoshinami N, Mizuno M, Sendo R, Tanaka S, Shintani H, Kagawa K, Okanoue T, Itoh Y.

Hepatol Res. 2014 Dec;44(13):1329-38. doi: 10.1111/hepr.12308. Epub 2014 Apr 2.

PMID:
24528772
39.

Interleukin 28B polymorphism predicts interferon plus ribavirin treatment outcome in patients with hepatitis C virus-related liver cirrhosis: A multicenter retrospective study in Japan.

Shakado S, Sakisaka S, Okanoue T, Chayama K, Izumi N, Toyoda J, Tanaka E, Ido A, Takehara T, Yoshioka K, Hiasa Y, Nomura H, Seike M, Ueno Y, Kumada H.

Hepatol Res. 2014 Sep;44(9):983-92. doi: 10.1111/hepr.12280. Epub 2014 Jan 9.

PMID:
24400682
40.

Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients.

Nakahara T, Hyogo H, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Ono M, Kawaguchi T, Imajo K, Aikata H, Tanaka S, Kanemasa K, Fujimoto K, Anzai K, Saibara T, Sata M, Nakajima A, Itoh Y, Chayama K, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease.

J Gastroenterol. 2014 Nov;49(11):1477-84. doi: 10.1007/s00535-013-0911-1. Epub 2013 Nov 26.

PMID:
24277052
41.

Long-term (>=2 yr) efficacy of vitamin E for non-alcoholic steatohepatitis.

Sumida Y, Naito Y, Tanaka S, Sakai K, Inada Y, Taketani H, Kanemasa K, Yasui K, Itoh Y, Okanoue T, Yoshikawa T.

Hepatogastroenterology. 2013 Sep;60(126):1445-50. doi: 10.5754/hge11421.

PMID:
23933938
42.

Lepr(db/db) Mice with senescence marker protein-30 knockout (Lepr(db/db)Smp30(Y/-)) exhibit increases in small dense-LDL and severe fatty liver despite being fed a standard diet.

Kondo Y, Hasegawa G, Okada H, Senmaru T, Fukui M, Nakamura N, Sawada M, Kitawaki J, Okanoue T, Kishimoto Y, Amano A, Maruyama N, Obayashi H, Ishigami A.

PLoS One. 2013 Jun 3;8(6):e65698. doi: 10.1371/journal.pone.0065698. Print 2013.

43.

Pathogenic Role of Iron Deposition in Reticuloendothelial Cells during the Development of Chronic Hepatitis C.

Mitsuyoshi H, Yasui K, Yamaguchi K, Minami M, Okanoue T, Itoh Y.

Int J Hepatol. 2013;2013:686420. doi: 10.1155/2013/686420. Epub 2013 Apr 4.

44.

Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats.

Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, Kimura H, Nishimura T, Tochiki N, Yasui K, Mitsuyoshi H, Minami M, Kagawa K, Okanoue T, Itoh Y.

Liver Int. 2013 Feb;33(2):301-11. doi: 10.1111/liv.12033.

PMID:
23295058
45.

[A case of HER2-positive and AFP-producing gastric cancer successfully treated by trastuzumab/docetaxel/S-1 combination therapy].

Amano I, Sawai N, Mizuno C, Shaura Y, Nishiwaki M, Horimoto R, Oya H, Kato R, Seki K, Hashimoto H, Amakata Y, Matsumoto J, Tanaka I, Mizuno M, Shima T, Okanoue T.

Gan To Kagaku Ryoho. 2012 Dec;39(13):2541-4. Japanese.

PMID:
23235175
46.

Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels.

Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, Ono M, Suzuki Y, Kawaguchi T, Aoki N, Sata M, Kanemasa K, Kohgo Y, Saibara T, Chayama K, Itoh Y, Yoshikawa T, Anzai K, Fujimoto K, Okanoue T, Nakajima A; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD).

J Gastroenterol. 2013 Sep;48(9):1051-60. doi: 10.1007/s00535-012-0704-y. Epub 2012 Nov 27.

PMID:
23184095
47.

High serum levels of both carcinoembryonic antigen and carbohydrate antigen 19-9 in a patient with sigmoid colon cancer without metastasis.

Nakatani H, Kumon T, Kumon M, Hamada S, Okanoue T, Kawamura A, Nakatani K, Hiroi M, Hanazaki K.

J Med Invest. 2012;59(3-4):280-3.

48.

Prediction of a favorable clinical course in hepatitis C virus carriers with persistently normal serum alanine aminotransferase levels: A long-term follow-up study.

Nishimura T, Yamaguchi K, Fujii H, Okada Y, Yokomizo C, Niimi T, Sumida Y, Yasui K, Mitsuyoshi H, Minami M, Umemura A, Shima T, Okanoue T, Itoh Y.

Hepatol Res. 2013 May;43(5):557-62. doi: 10.1111/j.1872-034X.2012.01091.x. Epub 2012 Sep 14.

PMID:
22978477
49.

Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus.

Shima T, Uto H, Ueki K, Takamura T, Kohgo Y, Kawata S, Yasui K, Park H, Nakamura N, Nakatou T, Tanaka N, Umemura A, Mizuno M, Tanaka J, Okanoue T.

J Gastroenterol. 2013 Apr;48(4):515-25. doi: 10.1007/s00535-012-0653-5. Epub 2012 Aug 22.

PMID:
22911170
50.

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese.

Kawaguchi T, Sumida Y, Umemura A, Matsuo K, Takahashi M, Takamura T, Yasui K, Saibara T, Hashimoto E, Kawanaka M, Watanabe S, Kawata S, Imai Y, Kokubo M, Shima T, Park H, Tanaka H, Tajima K, Yamada R, Matsuda F, Okanoue T; Japan Study Group of Nonalcoholic Fatty Liver Disease.

PLoS One. 2012;7(6):e38322. doi: 10.1371/journal.pone.0038322. Epub 2012 Jun 14.

Supplemental Content

Loading ...
Support Center